Clinical trial
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in…
NCT00454571 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00454571 |
|---|---|
| Title | Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer |
| Official title | A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer |
| Intervention type | Drug |
| Interventions | pazopanib hydrochloride, leuprolide acetate, goserelin acetate |
| Enrollment | 37 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Mar 30, 2007 |
| Last update posted | Feb 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: